Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events

Journals

1. Ma Y, Hou L, Yu F, Lu G, Qin S, Xie R, Yang H, Wu T, Luo P, Chai L, Lv Z, Peng X, Wu C, Fu D. Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer. Oncotarget 2017;8(11):18417 View
2. Sanchez-Duque J, Gaviria-Mendoza A, Moreno-Gutierrez P, Machado-Alba J. Big data, farmacoepidemiología y farmacovigilancia. Revista de la Facultad de Medicina 2020;68(1) View
3. Wu M, Yu Q, Li Q. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget 2016;7(50):82074 View
4. Cheng Y, Wu R, Cheng M, Du J, Hu X, Yu L, Zhao X, Yao Y, Long Q, Zhu L, Zhu J, Huang N, Liu H, Hu Y, Wan F. Carboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions. Oncotarget 2017;8(19):32228 View
5. Hosomi K, Fujimoto M, Ushio K, Mao L, Kato J, Takada M, Yang J. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs. PLOS ONE 2018;13(10):e0204648 View
6. Yokoyama S, Sugimoto Y, Nakagawa C, Hosomi K, Takada M. Integrative analysis of clinical and bioinformatics databases to identify anticancer properties of digoxin. Scientific Reports 2019;9(1) View
7. Vanhaelen Q, Mamoshina P, Aliper A, Artemov A, Lezhnina K, Ozerov I, Labat I, Zhavoronkov A. Design of efficient computational workflows for in silico drug repurposing. Drug Discovery Today 2017;22(2):210 View
8. Lin Y, He S, Feng R, Xu Z, Chen W, Huang Z, Liu Y, Zhang Q, Zhang B, Wang K, Wu S. Digoxin-induced anemia among patients with atrial fibrillation and heart failure: clinical data analysis and drug-gene interaction network. Oncotarget 2017;8(34):57003 View
9. Zamami Y, Imanishi M, Takechi K, Ishizawa K. Pharmacological approach for drug repositioning against cardiorenal diseases. The Journal of Medical Investigation 2017;64(3.4):197 View
10. Hamano H, Ikeda Y, Goda M, Fukushima K, Kishi S, Chuma M, Yamashita M, Niimura T, Takechi K, Imanishi M, Zamami Y, Horinouchi Y, Izawa-Ishizawa Y, Miyamoto L, Ishizawa K, Fujino H, Tamaki T, Aihara K, Tsuchiya K. Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity. Kidney International 2021;99(4):885 View
11. Chrétien B, Jourdan J, Davis A, Fedrizzi S, Bureau R, Sassier M, Rochais C, Alexandre J, Lelong‐Boulouard V, Dolladille C, Dallemagne P. Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease. British Journal of Clinical Pharmacology 2021;87(7):2830 View
12. Battini V, Van Manen R, Gringeri M, Mosini G, Guarnieri G, Bombelli A, Pozzi M, Nobile M, Radice S, Clementi E, Carnovale C. The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase. Frontiers in Pharmacology 2023;14 View
13. Zhou J, Torres V. Drug repurposing in autosomal dominant polycystic kidney disease. Kidney International 2023;103(5):859 View
14. Yao H. Virtual Screening of Natural Chemical Databases to Search for Potential ACE2 Inhibitors. Molecules 2022;27(5):1740 View
15. Liu Y, Liu Y, Fan R, Kehriman N, Zhang X, Zhao B, Huang L. Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis. European Journal of Medical Research 2023;28(1) View
16. Morris R, Ali R, Cheng F. Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database. Current Drug Targets 2024;25(7):454 View